We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

306 hedge funds and large institutions have $9.95B invested in BioMarin Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 101 increasing their positions, 115 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $94.9M | Put options by funds: $58.2M

31% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 39

4% more funds holding

Funds holding: 294 → 306 (+12)

2% less capital invested

Capital invested by funds: $10.1B → $9.95B (-$167M)

12% less repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 115

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

Holders
306
Holders Change
+12
Holders Change %
+4.08%
% of All Funds
8.88%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.2%
New
51
Increased
101
Reduced
115
Closed
39
Calls
$94.9M
Puts
$58.2M
Net Calls
+$36.7M
Net Calls Change
+$3.33M

Top Buyers

1
Wells Fargo
Wells Fargo
California
+$97.2M
2
BBA
Baker Bros. Advisors
New York
+$78.6M
3
Alkeon Capital Management
Alkeon Capital Management
New York
+$68M
4
Millennium Management
Millennium Management
New York
+$60.7M
5
State Street
State Street
Massachusetts
+$50M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$265M
2
GIM
Granahan Investment Management
Massachusetts
-$40.1M
3
Goldman Sachs
Goldman Sachs
New York
-$39.5M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$38.4M
5
ACPU
Arrowgrass Capital Partners (US)
Delaware
-$34.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
226
Janus Henderson Group
United Kingdom
$614K – – –
WBC
227
Westpac Banking Corp
Australia
$606K +$12.3K +181 +2%
VKH
228
Virtu KCG Holdings
New York
$602K -$250K -3,687 -30%
PIM
229
Platinum Investment Management
Australia
$599K – – –
Calamos Advisors
230
Calamos Advisors
Illinois
$583K +$265K +3,900 +89%
AAM
231
Azzad Asset Management
Virginia
$567K – – –
V
232
Veritable
Delaware
$559K – – –
GCP
233
GSA Capital Partners
United Kingdom
$535K +$517K +7,609 New
HIMCH
234
Hartford Investment Management Co (HIMCO)
Connecticut
$502K -$161K -2,370 -25%
SCM
235
Stux Capital Management
New York
$499K +$6.79K +100 +1%
WAM
236
World Asset Management
Michigan
$498K -$234K -3,450 -33%
CAN
237
Cetera Advisor Networks
California
$489K -$23.8K -350 -5%
CAM
238
Capstone Asset Management
Texas
$482K -$562K -8,272 -55%
P
239
Pitcairn
Pennsylvania
$459K -$80.7K -1,188 -15%
Connor, Clark & Lunn Investment Management (CC&L)
240
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$436K +$396K +5,830 New
PCP
241
Perimeter Capital Partners
Georgia
$420K +$202K +2,970 +99%
KeyBank National Association
242
KeyBank National Association
Ohio
$415K +$34K +500 +9%
Commonwealth Equity Services
243
Commonwealth Equity Services
Massachusetts
$406K +$392K +5,772 New
WSA
244
Wall Street Associates
California
$363K -$3.4K -50 -1%
PCM
245
Prelude Capital Management
New York
$356K – – –
SIM
246
SSI Investment Management
California
$348K +$336K +4,953 New
IIM
247
Intact Investment Management
Quebec, Canada
$330K +$67.9K +1,000 +27%
Daiwa Securities Group
248
Daiwa Securities Group
Japan
$310K – – –
TRCT
249
Tower Research Capital (TRC)
New York
$310K +$131K +1,923 +78%
DCMA
250
Daiwa Capital Markets America
New York
$310K +$299K +4,400 New
8 9
10
11 12

BMRN Hedge Fund Activity: Q4 2013 in Review

306 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2013, worth a combined $9.95B — down 1.7% from $10.1B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new BMRN positions and 39 closed out — a net gain of 12 holders — while 101 added to existing stakes and 115 trimmed.

The largest buyer was Wells Fargo, adding an estimated $97.2M. The largest seller was Fidelity Investments, cutting an estimated $265M.

  • 306 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2013, up from 294 in Q3 2013.
  • Funds reported $9.95B of BioMarin Pharmaceuticals stock for Q4 2013, down 1.7% quarter-over-quarter.
  • 51 funds opened new BioMarin Pharmaceuticals positions in Q4 2013 and 39 closed out, a net change of +12 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2013 was Wells Fargo, an estimated $97.2M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $265M sold.

Based on aggregated 13F filings for Q4 2013.